Wells Fargo Analyst Boosts Bath & Body Works to Buy Rating, Sets Price Target of $44.00

Phreesia Inc Director Lisa Egbuonu-davis sold 465 shares on July 15, 2025, after which she owns 21,572 shares. The healthcare technology company provides a patient intake management platform that automates the process, improving efficiency and patient experience. Over the past year, there have been 97 insider sells, and shares of Phreesia Inc were trading at $27.64 on the day of the sale, with a market cap of $1.542 billion.

On July 15, 2025, Lisa Egbuonu-Davis, a Director at Phreesia Inc (NASDAQ:PHR), sold 465 shares of common stock at a price of $27.64 per share, totaling $12,852. This transaction reduced Egbuonu-Davis's direct ownership of Phreesia shares to 21,572. The sale was executed under a Rule 10b5-1 trading plan adopted on September 24, 2024 [3].

Phreesia Inc is a healthcare technology company that provides a patient intake management platform designed to automate the process, enhancing efficiency and improving patient experience. The company has seen significant insider activity over the past year, with a total of 97 insider sells reported [1]. As of the date of the sale, Phreesia Inc's stock was trading at $27.64, with a market capitalization of $1.542 billion [3].

Phreesia's recent financial performance has been strong. In the first quarter of 2025, the company reported earnings that exceeded consensus estimates for both revenue and adjusted EBITDA. The Subscription and Services segment grew by 16%, driven by non-recurring revenue of approximately $1 million. Despite challenges in the Network Solutions segment, Phreesia maintained robust profitability, with adjusted EBITDA soaring by 408% to $20.8 million [3].

Analysts have responded positively to Phreesia's financial results. Piper Sandler maintained an Overweight rating with a $33 target, citing strong quarterly results and increased guidance for fiscal year 2026. Canaccord Genuity adjusted its price target to $34 but kept a Buy rating, acknowledging continued growth and profitability. DA Davidson reiterated a Buy rating with a $34 target, highlighting Phreesia's balance between profit growth and certain challenges. Raymond James maintained an Outperform rating with a $30 target, emphasizing strong margins and strategic investments. JPMorgan expressed optimism about Phreesia's growth prospects, reiterating an Overweight rating due to revenue diversification and recent profitability improvements [3].

References:
[1] https://www.tradingview.com/news/tradingview:4f6ddcc39c3e0:0-phreesia-executives-conduct-stock-transactions/
[2] https://www.phreesia.com/products/answer-every-call/
[3] https://www.investing.com/news/insider-trading-news/phreesia-director-egbuonudavis-sells-12852-in-stock-93CH-4140881